Home
Live Updates
ALIGN Study: Atrasentan Shows Significant Benefit on Proteinuria in IgAN at 36 Weeks : comparemela.com
ALIGN Study: Atrasentan Shows Significant Benefit on Proteinuria in IgAN at 36 Weeks
Atrasentan significantly reduces proteinuria in patients with IgA nephropathy, showing a 36.1% reduction compared to placebo at 36 weeks.
Related Keywords
Bonnie Schneider ,
Hiddo Heerspink ,
Igan Foundation ,
George Institute For Global Health Hiddo Heerspink ,
Department Of Clinical Pharmacy ,
Novartis ,
European Renal Association Congress ,
University Medical Center Groningen ,
George Institute ,
Global Health ,
Clinical Trials ,
Personalized Medicine ,
Clinical Pharmacy ,
University Medical Center ,
comparemela.com © 2020. All Rights Reserved.